GenSight Biologics postpones IPO

(Renaissance Capital's research analysts) GenSight Biologics, which is developing gene therapies for rare retinal diseases, postponed its IPO.
The Paris, France-based company was founded in 2012 and booked $2 million in sales for the 12 months ended June 30, 2015. It had planned to list on the Nasdaq under the symbol GNST. Leerink Partners, Evercore ISI and Canaccord Genuity were set to be the joint bookrunners on the deal.

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.